Published in Cancer Res on March 15, 1995
Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling. Mol Cell Biol (2009) 3.25
Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev (2000) 2.72
Lung cancer cell lines as tools for biomedical discovery and research. J Natl Cancer Inst (2010) 1.92
High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci U S A (1995) 1.76
The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression. Mol Cell Biol (2005) 1.60
Cellular and molecular parameters of mesothelioma. J Cell Biochem (2006) 1.57
Human semaphorins A(V) and IV reside in the 3p21.3 small cell lung cancer deletion region and demonstrate distinct expression patterns. Proc Natl Acad Sci U S A (1996) 1.48
Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma. Clin Cancer Res (2011) 1.47
Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma. Cancer Res (2014) 1.11
MYO18B, a candidate tumor suppressor gene at chromosome 22q12.1, deleted, mutated, and methylated in human lung cancer. Proc Natl Acad Sci U S A (2002) 1.10
New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment. Clin Cancer Res (2012) 1.03
Universal absence of merlin, but not other ERM family members, in schwannomas. Am J Pathol (1997) 1.02
TGF-β synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth. J Exp Med (2012) 1.01
A Phosphotyrosine Proteomic Screen Identifies Multiple Tyrosine Kinase Signaling Pathways Aberrantly Activated in Malignant Mesothelioma. Genes Cancer (2010) 0.93
Deregulation of the Hippo pathway in soft-tissue sarcoma promotes FOXM1 expression and tumorigenesis. Proc Natl Acad Sci U S A (2015) 0.89
NF2/merlin in hereditary neurofibromatosis 2 versus cancer: biologic mechanisms and clinical associations. Oncotarget (2014) 0.89
Chemotherapy for malignant pleural mesothelioma: a review of current management and a look to the future. Ann Cardiothorac Surg (2012) 0.87
Hippo/YAP pathway for targeted therapy. Transl Lung Cancer Res (2014) 0.87
Yes-associated protein 1 is activated and functions as an oncogene in meningiomas. Mol Cancer Res (2012) 0.86
Oncogenes and tumor-suppressor genes in mesothelioma--a synopsis. Environ Health Perspect (1997) 0.86
Role of Merlin/NF2 inactivation in tumor biology. Oncogene (2015) 0.85
Pathological and molecular biological approaches to early mesothelioma. Int J Clin Oncol (2012) 0.84
Factors that impact susceptibility to fiber-induced health effects. J Toxicol Environ Health B Crit Rev (2011) 0.84
Convergent signaling in the regulation of connective tissue growth factor in malignant mesothelioma: TGFβ signaling and defects in the Hippo signaling cascade. Cell Cycle (2012) 0.84
Deletions at 14q in malignant mesothelioma detected by microsatellite marker analysis. Br J Cancer (1999) 0.83
Merlin: the wizard requires protein stability to function as a tumor suppressor. Biochim Biophys Acta (2012) 0.82
Current issues in malignant pleural mesothelioma evaluation and management. Oncologist (2014) 0.81
Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas. Oncotarget (2016) 0.81
Evaluation of NF2 gene deletion in sporadic schwannomas, meningiomas, and ependymomas by chromogenic in situ hybridization. Hum Pathol (2007) 0.81
Important recent insights into the genetics and biology of malignant pleural mesothelioma. Ann Cardiothorac Surg (2012) 0.81
Syntenic relationships between genomic profiles of fiber-induced murine and human malignant mesothelioma. Am J Pathol (2011) 0.81
Multistep phosphorylation by oncogenic kinases enhances the degradation of the NF2 tumor suppressor merlin. Neoplasia (2011) 0.81
Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies. Expert Rev Respir Med (2015) 0.81
Molecular biology of malignant mesothelioma. Environ Health Prev Med (2008) 0.80
Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma. BMC Cancer (2015) 0.80
Tsc1-Tp53 loss induces mesothelioma in mice, and evidence for this mechanism in human mesothelioma. Oncogene (2013) 0.80
Establishment of immortalized murine mesothelial cells and a novel mesothelioma cell line. In Vitro Cell Dev Biol Anim (2015) 0.79
Reduced Fhit protein expression in human malignant mesothelioma. Virchows Arch (2003) 0.79
Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors. Clin Cancer Res (2016) 0.78
The human Rgr oncogene is overexpressed in T-cell malignancies and induces transformation by acting as a GEF for Ras and Ral. Oncogene (2011) 0.78
The biomolecular era for thoracic surgeons: the example of the ESTS Biology Club. J Thorac Dis (2014) 0.77
Inflammation-Related IL1β/IL1R Signaling Promotes the Development of Asbestos-Induced Malignant Mesothelioma. Cancer Prev Res (Phila) (2016) 0.77
Loss of tumor suppressor Merlin results in aberrant activation of Wnt/β-catenin signaling in cancer. Oncotarget (2016) 0.77
Recent insights emerging from malignant mesothelioma genome sequencing. J Thorac Oncol (2015) 0.77
Expression of cancer-associated molecules in malignant mesothelioma. Biomark Insights (2007) 0.77
Asbestos and mesothelioma: genetic lessons from a tragedy. Proc Natl Acad Sci U S A (1995) 0.77
Binding of the merlin-I product of the neurofibromatosis type 2 tumour suppressor gene to a novel site in beta-fodrin is regulated by association between merlin domains. Biochem J (2001) 0.76
Practical approaches to diagnose and treat for T0 malignant pleural mesothelioma: a proposal for diagnostic total parietal pleurectomy. Int J Clin Oncol (2012) 0.76
Unique fractal evaluation and therapeutic implications of mitochondrial morphology in malignant mesothelioma. Sci Rep (2016) 0.75
Functional differences between wild-type and mutant-type BRCA1-associated protein 1 tumor suppressor against malignant mesothelioma cells. Cancer Sci (2015) 0.75
Establishment and molecular characterization of cell lines from Japanese patients with malignant pleural mesothelioma. Oncol Lett (2015) 0.75
Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X. Mod Pathol (2016) 0.75
Molecular profiling reveals primary mesothelioma cell lines recapitulate human disease. Cell Death Differ (2016) 0.75
Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A (1980) 30.08
Positive control of a regulon for defenses against oxidative stress and some heat-shock proteins in Salmonella typhimurium. Cell (1985) 12.51
Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res (1987) 10.80
p53: a frequent target for genetic abnormalities in lung cancer. Science (1989) 7.51
Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature (1984) 6.23
Mitogen requirements for the in vitro propagation of cutaneous T-cell lymphomas. Blood (1980) 6.17
Hydrogen peroxide-inducible proteins in Salmonella typhimurium overlap with heat shock and other stress proteins. Proc Natl Acad Sci U S A (1986) 5.29
Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res (1985) 5.02
L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer. Nature (1985) 4.66
Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature (1985) 4.47
Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science (1988) 4.26
Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst (2001) 4.14
Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. Proc Natl Acad Sci U S A (1990) 4.06
Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Mol Cell (1998) 3.86
An alkyl hydroperoxide reductase from Salmonella typhimurium involved in the defense of DNA against oxidative damage. Purification and properties. J Biol Chem (1989) 3.74
The leader mRNA of the histidine attenuator region resembles tRNAHis: possible general regulatory implications. Proc Natl Acad Sci U S A (1983) 3.43
Continuous, clonal, insulin- and somatostatin-secreting cell lines established from a transplantable rat islet cell tumor. Proc Natl Acad Sci U S A (1980) 3.39
NCI-Navy Medical Oncology Branch cell line data base. J Cell Biochem Suppl (1996) 3.24
Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int J Cancer (1998) 3.12
Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci U S A (1990) 3.03
Molecular genetics of small cell lung carcinoma. Semin Oncol (2001) 3.02
Pol kappa: A DNA polymerase required for sister chromatid cohesion. Science (2000) 2.92
p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J (1992) 2.90
Molecular damage in the bronchial epithelium of current and former smokers. J Natl Cancer Inst (1997) 2.83
Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer. Oncogene (2008) 2.83
Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res (2001) 2.80
NCI series of cell lines: an historical perspective. J Cell Biochem Suppl (1996) 2.75
Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier. Cancer Res (1998) 2.72
A new Salmonella tester strain (TA102) with A X T base pairs at the site of mutation detects oxidative mutagens. Proc Natl Acad Sci U S A (1982) 2.67
p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene (1992) 2.64
Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer. Nature (1987) 2.59
Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity. Cancer Res (1987) 2.56
Spontaneous mutagenesis and oxidative damage to DNA in Salmonella typhimurium. Proc Natl Acad Sci U S A (1987) 2.51
Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology. Clin Cancer Res (2001) 2.50
Chromosome 19 translocation, overexpression of Notch3, and human lung cancer. J Natl Cancer Inst (2000) 2.45
Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol (2007) 2.43
Localization of bronchial intraepithelial neoplastic lesions by fluorescence bronchoscopy. Chest (1998) 2.39
Chemotherapy for non-small cell lung cancer. BMJ (1995) 2.39
Widely dispersed p53 mutation in respiratory epithelium. A novel mechanism for field carcinogenesis. J Clin Invest (1997) 2.30
Ion mobility spectrometry for the detection of volatile organic compounds in exhaled breath of patients with lung cancer: results of a pilot study. Thorax (2009) 2.28
Prevalence and specificity of LKB1 genetic alterations in lung cancers. Oncogene (2007) 2.27
Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. Cancer Res (2000) 2.24
Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene (2001) 2.22
Simian virus 40-like DNA sequences in human pleural mesothelioma. Oncogene (1994) 2.21
Telomerase activity in small-cell and non-small-cell lung cancers. J Natl Cancer Inst (1995) 2.18
Conservation of autosomal gene synteny groups in mouse and man. Nature (1978) 2.18
Eukaryotic DNA polymerases: proposal for a revised nomenclature. J Biol Chem (2001) 2.15
Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification. Oncogene (2006) 2.14
Deregulated expression of human c-jun transforms primary rat embryo cells in cooperation with an activated c-Ha-ras gene and transforms rat-1a cells as a single gene. Proc Natl Acad Sci U S A (1989) 2.13
Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium. Cancer Res (1986) 2.12
Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties. Cancer Res (1985) 2.12
Establishment of continuous, clonable cultures of small-cell carcinoma of lung which have amine precursor uptake and decarboxylation cell properties. Cancer Res (1980) 2.10
Mutation analysis of the PTEN/MMAC1 gene in lung cancer. Oncogene (1998) 2.10
Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res (1992) 2.09
Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res (2000) 2.07
High levels of intracellular bombesin characterize human small-cell lung carcinoma. Science (1981) 2.07
Detection and sequencing of p53 gene mutations in bronchial biopsy samples in patients with lung cancer. Chest (1993) 2.06
Identification of mouse chromosomes required for murine leukemia virus replication. Cell (1977) 2.05
Multiple clonal abnormalities in the bronchial epithelium of patients with lung cancer. J Natl Cancer Inst (1999) 2.03
Opioid and nicotine receptors affect growth regulation of human lung cancer cell lines. Proc Natl Acad Sci U S A (1990) 2.02
Serum neuron-specific enolase: a marker for disease extent and response to therapy of small-cell lung cancer. Lancet (1982) 2.02
Specific chromosome defect associated with human small-cell lung cancer; deletion 3p(14-23). Science (1982) 2.02
Simian virus-40 large-T antigen binds p53 in human mesotheliomas. Nat Med (1997) 2.01
Gene mapping in Mus musculus by interspecific cell hybridization: assignment of the genes for tripeptidase-1 to chromosome 10, dipeptidase-2 to chromosome 18, acid phosphatase-1 to chromosome 12, and adenylate kinase-1 to chromosome 2. Cytogenet Cell Genet (1977) 1.98
Motivations and perceptions of early adopters of personalized genomics: perspectives from research participants. Public Health Genomics (2011) 1.96
Human small-cell lung cancers show amplification and expression of the N-myc gene. Proc Natl Acad Sci U S A (1986) 1.96